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As the role of distal fallopian tube as organ of serous carcinogenesis is emerging, additional literature on the role of tubal
intraepithelial carcinoma (TIC) as a precursor lesion in a subset of primary peritoneal serous carcinomas (PPSC is emerging
as well. TIC although fallopian tube in origin can be genetically related to ovarian/peritoneal carcinomas. The role of PAX2 in
primary fallopian tube carcinomas (PFTC)/PPSC is yet to be deﬁned. The aim of our study was to understand if the biologic
properties of tumors arising in the distal fallopian tube that remain as PFTC are diﬀerent when they seed on to the peritoneal
surface (PPSC). A panel of 6 polymorphic microsatellite markers corresponding to p53, PAX2, and WT1 tumor suppressor genes
were studied. Invasive carcinomas as well as TIC arising in the distal fallopian tube when remain as PFTC appears to exhibit
diﬀerent LOH patterns in comparison to PPSC. PAX 2 LOH patterns might represent a “hidden PAX 2 signature” analogous to
p53 signatures. PAX 2 might be an emerging marker for detection of early serous carcinomas particularly in BRCA + women.
1.Introduction
Ovarian cancer is divided into two (2) histopathologic
groups with distinct molecular pathogenesis as well as pro-
pensity for extra ovarian spread. Group 1 includes tumors
of borderline malignancy, low-grade serous carcinomas,
endometrioid and mucinous carcinomas. These tumors
arise from ovarian parenchyma, conﬁned to one or more
cysts, and do not typically originate from or involve the
ovarian surface and often exhibit BRAF, KRAS, P-TEN,
b-catenin mutations. Group 2 includes serous carcinomas
that arise from the ovarian surface epithelium or mullerian
inclusions, fallopian tube mucosa, and mullerian epithelium
in peritoneal cavity and often exhibit p53 mutations; these
tumors are rapidly evolving and lethal [1]. Primary fallopian
tube carcinomas (PFTCs) that arise from the mucosa of
the fallopian tube, accounts for less than 1% of all female
genital tract carcinomas [2]. Morphologic features such as
dominant, centrally located mass in fallopian tube, presence
ofinsitucarcinoma,absenceofcoexistingendometrialcarci-
noma, minimal ovarian involvement, qualiﬁes these tumors
as PFTC. Histologically, these tumors are predominantly of
“serous” morphology. Primary peritoneal serous carcinomas
(PPSCs) though morphologically resemble ovarian serous
carcinomas (OSCs); the ovaries are either normal or mini-
mally involved [2]. Coexisting intraepithelial neoplasia is a
prerequisite for PFTC diagnosis; on contrary, PPSC are often
diagnosed in the absence of an “in situ” lesion. Based on the2 ISRN Obstetrics and Gynecology
tumor distribution, these tumors are interclassiﬁed as OSC
or PPSC. Tubal intraepithelial carcinoma (TIC) is neoplastic
transformation of benign tubal epithelium. Presence of TIC
designates tube as “primary tumor site”. Recent studies by
Crum et al. have shown the association of TIC in 47% (5/8)
of PPSC and 37% (19/39) OSC cases [3–5]. The group has
also established TIC as an earliest manifestation of pelvic
serous carcinoma in both BRCA+/sporadic tubal carcinomas
[3,6].Astheroleofdistalfallopiantubeasanorganofserous
carcinogenesisisemerging,theprimaryaimofourstudywas
to understand if the biologic properties of tumors arising in
distal fallopian tube that remain as PFTC are diﬀerent when
seeds on peritoneal surface (PPSC). TIC though fallopian
tubeinorigincanbegeneticallyrelatedtoovarian/peritoneal
carcinomas, and our secondary goal was to understand the
biologic properties of TIC in association with PFTC from
PPSC w/associated TIC.
2.MaterialsandMethods
MWH pathology ﬁles were searched between the years
January 2006— December 2009. All tumors that met WHO
2001 criteria for PPSC were selected [2].
The criteria included the following
(i) Both ovaries normal size/enlarged by benign process.
(ii) Extra ovarian involvement > surface of ovaries.
(iii) Ovarian involvement-nonexistent—conﬁned to sur-
face w/no stromal invasion (< 5 ×5cm).
SEE-FIM protocol, a procedure for sectioning the entire
ﬁmbriated end (SEE-FIM protocol) in prophylactic oopho-
rectomy specimens tubes, are ﬁrst ﬁxed for 4–6 hours: the
ﬁmbriated end (a) is amputated, (b) open-sectioned longi-
tudinally to expose the maximum surface area, (c) submitted
in toto with the remainder of the tube sectioned at 2-3mm
intervals, was adopted at MWH in 2006 [7].
PPSC were grouped into tumors with associated TIC in
the adjacent fallopian tubes and tumors without associated
TIC.
All tumors that met the WHO criteria for PFTC were
selected as well [2].
Hematoxylin & Eosin (H&E) slides were reviewed and
the diagnosis was conﬁrmed.
Figures 1, 2,a n d3 show the histologic and IHC expres-
sion for PAX 2, WT-1, and p53 markers.
Representative tumor blocks as well as associated TIC in
the corresponding fallopian tube sections were selected.
Wilm’s tumor gene 1 (WT-1), p53, and PAX 2 gene
markers were selected for loss of heterozygosity (LOH) and
immunohistochemical (IHC) analysis.
2.1. Loss of Heterozygosity (LOH)
2.1.1. Microdissection and DNA Isolation. One or two paraf-
ﬁn blocks were selected to represent tumor and normal
tissue from each patient. Ten (10) serial sections were
obtained from paraﬃn-embedded tissue blocks. The ﬁrst
and last sections were stained with H&E to conﬁrm that
the intervening blank slides contained the lesional material.
Tissue fragments were microdissected under stereomicro-
scopic visualization from 6–8 blank deparaﬃnized slides
for each of the marked targets. Areas that contained large
amounts blood, necrosis, or contaminating normal tissue
were avoided during microdissection. DNA was isolated
using DNEasy tissue extraction kit (Qiagen, Chatsworth,
Calif.; USA). PCR ampliﬁcation was performed using ﬂuo-
rescently labeled primers ﬂanking microsatellite repeat poly-
morphisms located in close proximity to the speciﬁc genes
of interest. Six microsatellite loci situated adjacent to three
known tumor suppressor genes on chromosome 10q (PAX2
D10S.520, D10S.1173), 11p (WT-1 D11S.2370, D11S.995),
and 17p (p53 D17S.1844, D17S.516) were assessed.
2.2. Loss of Heterozygosity (LOH) Analysis. Ampliﬁcation
products were detected using ﬂuorescence capillary elec-
trophoresis and Gene Mapper Software 4.0 (ABI 3730,
Applied Biosystems, Foster City, CA). Allelic peak heights
of each electropherogram in relative ﬂuorescence units were
analyzed. The presence or absence of allelic imbalance
was accessed by comparing allelic peak heights for each
tumor sample with corresponding normal tissue. The sam-
ple was considered as noninformative (NI) if the tissue
sample demonstrates only a single peak. Individuals with
a heterozygous allele pattern (two peaks) were designated
as informative for that particular locus (Figure 4). Loss of
heterozygosity (LOH) was calculated using the following
formula: LOH = allele ratio [tumor]/allele ratio [normal]).
The sample was considered to have high level of allelic
imbalance if the allelic ratio for a speciﬁc microsatellite
marker was less than 0.5 or greater than 2.0 and to have low
level of allelic imbalance when the peak height ratios fall into
the range of 0.5–0,7 or 1.65–2.0.
2.3. Immunohistochemistry (IHC). Immunohistochemical
stains were performed on the blank sections on the
corresponding paraﬃn-embedded block selected for LOH
analysis. The details of the antibodies are speciﬁed in Table 1.
A strong “nuclear” staining is considered positive for all the
three antibodies WT-1, p53, and PAX 2. The intensity of
staining (IS) was graded as negative (0), weak (1), moderate
(2), and strong (3), and proportion of positive staining cells
(PS) was recorded as 0%–5% (1), 1%–20% (2), 21-80% (3)
and greater than 80% (4).
A cumulative score (CS) is calculated incorporating PS as
well as IS. The score is derived by the summation of PS and
IS, ranged from 0 to 7 and is further divided into Negative
(0), Weak (1-2); Moderate (3–5); Strong (6–7).
3. Results
All the tumors are categorized into three groups.
3.1. Group 1: PFTC in the Background of TIC (n-10).
This group included all cases of primary fallopian tube
carcinomas (PFTCs). All tumors (100%) were present in the
background of TIC.ISRN Obstetrics and Gynecology 3
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Figure 1: Hematoxylin and Eosin section of primary fallopian tube carcinoma (PFTC) with high grade serous papillary morphology:
“nuclear” expression for PAX 2, p53, and WT-1 immunostains.
Table 1: Antibodies, sources, and conditions.
Antibody Vendor Reference no. Clone Dilution Pre-Treatment Detection
WT-1 protein Cell Marque;
Rocklin, CA
CMA788 6F-H2 Pre-dilute
CC1 mild plus
Protease 3, 4
min; Vetana
Medical
Iview DAB plus
Ampliﬁcation;
Ventana
PAX-2
Zymed-
Invitrogen;
Carlsbad, CA
71–6000 Rabbit
Polyclonal
1:30 CC1 standard Iview DAB
P53 Ventana Medical;
Tucson, AZ
790–2912 DO-7 Pre-dilute CC1 standard Iview DAB
Table 2 shows the clinical and pathologic features of the
PFTC (Group 1) cases.
3.1.1. IHC and LOH Results of Group 1
PAX 2. there is heterogeneity in PAX 2 immunostain expres-
sioninbothTICaswellastheadjacentinvasivecarcinoma.A
moderate-strong staining is seen in 40% (4/10) cases of both
TICaswellastheadjacentinvasivecarcinoma.LOHwasseen
in up to 30% (3/10) in the invasive carcinomas. The foci of
TICw er eablet obecaptur edforL OHanalysisinfour(4)out
of ten (10) cases. LOH was in 75% (3/4) cases.
WT-1 and p53. immunohistochemical expression for WT-
1 and p53 were similarly seen consistently. A strong nuclear
staining is seen in 100% (10/10) of all TIC and 80% (8/10)
adjacent invasive carcinoma. LOH was seen in up to 50%
(2/4) of TIC and 30% (3/10) of invasive carcinomas.
3.2. Group 2: PPSC without Associated TIC (PPSC/-) (n-9).
This group includes all cases of PPSC without associated TIC
in the fallopian tubes.
3.2.1. IHC and LOH Results of Group 2
PAX 2. there is heterogeneity in the expression of PAX 2
within this group. A strong PAX expression is seen in 33.3%
(3/9)andmoderateexpressionin33.3%(3/9).LOHwasseen
in a higher frequency in 7/9 (79%) of cases.
WT-1 and p53. immunohistochemical expression for WT-
1 and p53 were similarly seen consistently. A strong nuclear4 ISRN Obstetrics and Gynecology
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Figure 2: Hematoxylin and Eosin (H&E) section of primary peritoneal serous carcinomas (PPSC) with high-grade serous papillary
morphology: “nuclear” expression for PAX 2, p53, and WT-1 immunostains.
PAX 2 P53 WT-1
TIC
Figure 3: Hematoxylin and Eosin (H&E) section of tubal intraepithelial carcinoma (TIC) with stratiﬁed epithelium, marked nuclear atypia
associated with a subset of PPSC as well as PFTC: “nuclear” expression for PAX 2, p53, and WT-1 immunostains.
staining is seen in 100% (10/10) of all TIC and 80% (8/10)
adjacent invasive carcinoma. LOH was seen in up to 44%
(4/9) at the WT-1 locus and 44% (4/9) at the p53 locus.
3.3.Group3:PPSCwithAssociatedTIC(PPSC/+)(n-5). This
group includes all cases of PPSC with associated TIC in the
fallopian tubes.
3.3.1. IHC and LOH Results of Group 3.
PAX 2. there is heterogeneity in the expression of PAX 2
immunostain expression in both TIC as well as PPSC. A
moderate-strong staining is seen in 40% (2/5) cases PPSC,
and 20% (1/5) of associated TIC. No LOH was seen in both
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Figure 4: This ﬁgure shows the Loss of Heterozygosity (LOH) patterns of the normal (a) in comparison to the corresponding tumor (b),
(c).
Table 2: Clinical and pathologic features of Group 1 [primary fallopian tube carcinoma (PFTC)] arising in the background of tubal
intraepithelial carcinoma (TIC).
PFTC (n-9) Age Histology Diagnosis Tumor size(cm) Lymph nodemetastasis FIGO stage
Positive Negative
Case 1 48 High grade serous 8.0 0 6 T1a
Case 2 81 High grade serous 0.8 0 6 T1a
Case 3 73 High grade serous 5.5 0 9 T2a
Case 4 58 High grade serous 3.0 0 9 T1a
Case 5 79 High grade serous 5.0 0 6 T1a
Case 6 71 High grade serous 4.5 1 4 T3c
Case 7 77 High grade serous 1.6 0 21 T3a
Case 8 44 High grade serous 6.0 6 15 T3c
Case 9 67 High grade serous 1.5 23 0 T3c
PFTC: Primary fallopian tube carcinomas.
WT-1 and p53. immunohistochemical expression for WT-
1 and p53 were similarly seen consistently. A strong nuclear
staining is seen in 100% (5/5) of all TIC and 80% (4/5)
adjacent invasive carcinoma. No LOH was seen in both TIC
as well as PPSC at the WT-1 or p53 gene loci. One (1)
out of ﬁve (5) cases showed LOH at WT-1 gene locus in
b o t hT I Ca sw e l la sP P S C .T a b l e s3, 4,a n d5 show the
immunohistochemical and LOH expression for PAX 2, WT-
1, and p53 gene markers.
4. Discussion
Primary fallopian tube carcinomas (PFTCs) are rare and
c o m p r i s e su pt o1 . 1 %o fa l lg y n e c o l o g i cc a n c e r s .I no r d e rt o
be considered for PTFC, the tumor must be macroscopically
located within the tube or at the ﬁmbriated end and the
uterus and ovary should be free of the tumor. Presence
of in situ carcinoma designated as TIC qualiﬁes “fallopian
tube” as the origin. A great majority of the tubal carcinomas6 ISRN Obstetrics and Gynecology
Table 3: Immunohistochemical (IHC) and loss of heterozygosity (LOH) analysis of Group 1: primary fallopian tube carcinoma (PFTC) and
associated tubal intraepithelial carcinoma (TIC).
PPSC/+ Associated TIC PFTC
PAX 2 WT-1 P53 PAX 2 WT-1 P53
∗IHC(CS) LOH ∗IHC (CS) LOH ∗IHC (CS) LOH ∗IHC(CS) LOH ∗IHC (CS) LOH ∗IHC (CS) LOH
Case 1 0 No LOH 7 No LOH 7 LOH 0N o L O H6N o L O H7 LOH
C a s e 2 037 N o L O H 3 LOH 7N o L O H7N o L O H
C a s e 3 6706 N o L O H 7 LOH 7N o L O H
C a s e 4 0776 N o L O H 7 LOH 7 LOH
Case 5 2 LOH 7 No LOH 0 3 No LOH 7 No LOH 0 No LOH
Case 6 7 LOH 6 LOH 7N o L O H7 LOH 7N o L O H7N o L O H
C a s e 70 7 7 0N o L O H7N o L O H7N o L O H
C a s e 8 377 ∗∗0 LOH 7N o L O H7 LOH
Case 9 ∗∗0 LOH 7 LOH ∗∗0 LOH 0N o L O H7 LOH 0N o L O H
Case 10 6 7 7 6 No LOH 7 No LOH 7 No LOH
∗IHC (CS): a cumulative score (CS) was calculated incorporating PS as well as IS. The score was derived by the summation of PS and IS, ranged from 0 to 8
and is further divided into Negative (0), Weak (1-2), Moderate (3–5), Strong (6–8).
(∗∗): PAX signature; (): 4 cases of TIC on which LOH was performed.
Table 4: Immunohistochemical (IHC) and loss of heterozygosity (LOH) analysis of Group 2: primary peritoneal serous carcinomas (PPSC)
without associated tubal intraepithelial carcinoma (TIC).
PPSC/− PAX 2 WT-1 P53
∗IHC (CS) LOH ∗IHC(CS) LOH ∗IHC(CS) LOH
Case 1 7 LOH 7 N oL O H 7 N oL O H
Case 2 ∗∗0 LOH 7 LOH 7N o L O H
Case 3 ∗∗0 LOH 7 N oL O H 7 N oL O H
Case 4 7 LOH 7 LOH 7 LOH
Case 5 ∗∗0 LOH 7 N oL O H 7 N oL O H
Case 6 7 No LOH 7 LOH 3 LOH
Case 7 3 LOH 7 LOH 7 LOH
C a s e8 3 N oL O H 7 N oL O H 7 N oL O H
Case 9 3 LOH 7N o L O H7 LOH
∗IHC (CS): a cumulative score (CS) was calculated incorporating PS as well as IS. The score was derived by the summation of PS and IS, ranged from 0 to 8
and is further divided into Negative (0), Weak (1-2), Moderate (3–5), Strong (6–8).
(∗∗): PAX signature.
are predominantly “serous” in histology. Primary peritoneal
serous carcinoma (PPSC) is diagnosed in the absence of an
“in situ” lesion. The spread of PPSC is similar to ovarian
carcinoma and sometimes involvement of adjacent ovary
makes it diﬃcult to determine the primary tumor origin and
often classiﬁed either as ovarian or primary peritoneal in
origin based on the “bulk of the tumor.”
Tubal intraepithelial carcinoma (TIC), though fallopian
tube in origin has been shown in recent studies to be
associated with nearly half of OSC as well as PPSC [3].
Further p53 analysis on both TIC as well as PPSC has shown
comparable mutational analysis genetically linking TIC as a
precursorlesiontosomeofthePPSC[7].Theseobservations
were further endorsed in a proposed model for pathogenesis
of pelvic serous carcinoma by Crum et al. In this proposed
model, when the normal tubal mucosa at the ﬁmbriated
end transforms into TIC, the tumor cells exfoliated into the
peritoneal surface and thus seeding extensively [8].
Distal fallopian tube (Fimbria) is a unique region with
large surface area exposed to biologic events that impact the
ovarian surface. It acts as a junction between mesothelium
and mullerian epithelium. The reported frequency of PFTC
at the ﬁmbriae ranges from 40%–100%. These tumors are
diagnosedeﬀortlesslyin thepresenceofadistended fallopian
tube with a large centrally located tumor. However most
of the tumors in this region are less commonly recognized
as PFTC when a microscopic invasive tumor or a focus of
TIC is present, until they spread to other sites. Additionally,
fallopian tubes are not thoroughly examined in all PPSC
for a tubal source. Interestingly, in the tumors arising from
the distal fallopian tube though they share a common
“precursor lesion” TIC, some of them appear to remain
as PFTC and others seed on to the peritoneal surface to
become PPSC. One of the primary goals of our study was
to understand the biologic properties of the tumors arising
in the distal fallopian tube that remain as PFTC are similarISRN Obstetrics and Gynecology 7
Table 5: Immunohistochemical (IHC) and loss of heterozygosity (LOH) analysis of Group 3: primary peritoneal serous carcinomas (PPSC)
with associated tubal intraepithelial carcinoma (TIC).
PPSC/+
Associated TIC PPSC
PAX 2 WT-1 P53 PAX 2 WT-1 P53
∗IHC(CS) LOH ∗IHC (CS) LOH ∗IHC (CS) LOH ∗IHC(CS) LOH ∗IHC (CS) LOH ∗IHC (CS) LOH
Case 1 1 No LOH 7 No LOH 7 No LOH 0 No LOH 7 No LOH 7 No LOH
Case 2 0 No LOH 7 No LOH 7 No LOH 4 No LOH 7 No LOH 7 No LOH
Case 3 5 No LOH 7 No LOH 7 No LOH 6 No LOH 7 No LOH 7 No LOH
Case 4 No LOH 7 No LOH 7 No LOH 0 No LOH 7 No LOH 6 No LOH
∗IHC (CS): a cumulative score (CS) was calculated incorporating PS as well as IS. The score was derived by the summation of PS and IS, ranged from 0 to 8
and is further divided into Negative (0), Weak (1-2), Moderate (3–5), Strong (6–8).
when they seed on to the peritoneal surface to become PPSC.
Two tumor suppressor gene markers p53 and WT-1 were
chosen along with an emerging mullerian marker PAX2 to
understand these biologic properties.
PAX2 gene, transcription factor expressed in the inter-
mediate mesoderm (Wolﬃa nd u c t sa sw e l la sm ¨ ullerian
ducts originate), is located on chromosome 10q24 [9].
PAX2 immunohistochemistry has shown to be a sensitive
marker for diagnosing nephrogenic adenomas and renal
cell carcinoma [10–12]. In the female genital organs, PAX
2 expression is seen in benign ﬁmbriae of the fallopian
tubes to the epithelium of the cervix. In the same study,
PAX2 expression is seen in up to (60%) of OSC cases.
In a recent published study, we have demonstrated a
diﬀuse PAX 2 expression in simple serous cysts, and serous
cystadenoﬁbromasaswellasovarianserouscarcinomas[13].
In the same study, we observed a diﬀuse PAX 2 expression in
secretory cells of the tubal epithelial lining [13, 14].
P53 is a tumor suppressor gene located on the short arm
of chromosome 17. Mutations of p53 are common in many
human cancers; overexpression of p53 protein is associated
with poor prognosis in a variety of cancers. Mutations of p53
are seen in Type 2, rapidly evolving tumors. P53 mutations
are seen in up to 75% (8/12) of p53 signatures and a much
higher incidence in TIC as well [7, 12].
WT-1 gene is consistently detected in both normal
ovarian germinal epithelium and human mesothelium. Loss
of normal WT-1 gene function is a common event in
both PPSC and advanced OSC due to downregulation by
regulatory factors. WT-1 immunohistochemical expression
was shown in majority of serous carcinomas of ovary,
fallopian tube as well as PPSC establishing as a highly
s e n s i t i v ea sw e l la ss p e c i ﬁ cm a r k e rf o rt u m o r so fm u l l e r i a n
diﬀerentiation [4, 5, 15–17]. In our study, LOH in the WT-1
gene locus was seen in up to 44% of cases in PPSC without
associated TIC group in contrast to one case (20%) in the
PPSC with associated TIC.
Using the three markers, we observed a great majority
of our PPSC without associated TIC exhibited LOH in the
PAX gene locus followed by WT-1 gene locus compared
to the other tumor groups. In the PFTC group, the LOH
patterns of both the TIC as well as the invasive carcinoma
were similar. In the tumors of distal fallopian tube with a
common TIC origin (that includes PFTC as well as subset
of PPSC); there exists a diﬀerence in the LOH patterns in
the tumors remaining as PFTC in comparison to the tumors
that seed on to the peritoneal surface (PPSC). The group
of PPSC arising in the absence of TIC exhibits diﬀerent
LOH patterns in comparison to PPSC w/associated TIC. Our
study demonstrates the “heterogeneity” that exists within
these tumors of the distal fallopian tube. Based on the
LOH patterns, it is possible that though these tumors share
the same “precursor lesion”, early or late events in genetic
stability are facilitating these tumors to follow the pathway
of developing into PPSC or to remain as PFTC. It is also
possible that the subset of PPSC in the absence of TIC might
arise within the mullerian foci of the peritoneal cavity thus
circumventing the tubal pathway. We further observed that
the TIC in association with PFTC demonstrates diﬀerent
LOH patterns in comparison to PPSC w/TIC also raising the
question of tubal origin in some of these tumors.
4.1. PAX 2 Signature. Fallopian tube has been shown to be
an organ of serous carcinogenesis. Early serous carcinomas
werediagnosedin2%–10%ofBRCA(+)womenundergoing
prophylactic bilateral salpingo-oopherectomies [12, 18]. p53
signatures are deﬁned as benign appearing tubal mucosa
that strongly expresses p53 mutations and show low MIB
1a c t i v i t y . These signatures are present in the distal tube
and predominate in “secretory” cells. p53 signature is seen
in 24% of BRCA patients and in association with TIC in
50% cases. This signature represents the initiation of serous
carcinogenesis in distal fallopian tube and is theorized that
women at high genetic risk are more likely to progress from
the p53 signature to TIC as well as invasive carcinoma.
Though we did not perform MIB 1 in our study to assess
the proliferation activity, interestingly in some of our PPSC
without TIC group, we have observed a small subset of cases
that showed LOH at the PAX 2 locus but no expression
by IHC. Though this may not be exactly similar to p53
signature, but appears to be an earliest genetic instability at
the PAX 2 locus exhibited by these tumors in comparison to
other tumors, might be representative of a type of “PAX 2
signature.” [19]
5. Conclusions
In conclusion, tumors arise in distal FT remaining as PFTC
appears to exhibit diﬀerent LOH patterns when seeds on8 ISRN Obstetrics and Gynecology
peritoneal surface (PPSC) though there is no diﬀerence in
the expression of these tumors by immunohistochemistry.
TIC in association with PFTC demonstrates diﬀerent LOH
patterns in comparison to PPSC w/TIC (? Tubal origin).
PAX 2 LOH patterns in PPSC represent “PAX signature.”
Understanding precursor lesions in distal fallopian tube
helps in detection of early serous carcinomas (BRCA). Our
study is the ﬁrst to demonstrate the LOH and IHC of
PAX2 in these tumors and might be an emerging biologic
markerforearlydetection.Studiesareinprogressusingthese
molecular markers in BRCA (+) women w/prophylactic
bilateral salpingo-oophorectomies.
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